A multiomic approach to prediction, causation, and prevention of preterm birth and preeclampsia
A multiomic approach to prediction, causation, and prevention of preterm birth and preeclampsia
Recent advances in both genomics, transcriptomics, and proteomics have allowed for the development of novel technologies with greater capabilities for biomarker profiling and discovery. When coupled with high-content data analysis, these multiomic approaches have allowed researchers to generate high-efficiency data to enable new correlations and insights between the genome, transcriptome, and proteome at a molecular level in health and disease. For example, an area of unmet need where multiomics is poised to impact significantly is pregnancy-related complications, such as preterm birth and preeclampsia. A better understanding of the molecular mechanisms of feto-maternal changes during pregnancy could help save lives and improve birthing processes.
Our distinguished presenters — members of the Gaudillière lab at Stanford University — describe how they employed a translational approach that combines single-cell mass cytometry with high-plex proteomic and metabolomic analyses to study the role of the human immune system in the pathobiology of fundamental clinical problems, including pregnancy pathologies. The presenters also explain how they used novel machine-learning methods to train multiomic models and identify biologically relevant predictive biomarkers to develop robust diagnostics rooted in a precise understanding of underlying pathobiological mechanisms.
Ina Stelzer, PhD
Instructor
Stanford University
Julien Hédou, MSc
Data Analyst
Stanford University
Dorien Feyaerts, PhD
Postdoctoral Fellow
Stanford University
A multiomic approach to prediction, causation, and prevention of preterm birth and preeclampsia
A presentation by Ina Stelzer, PhD, Julien Hédou, MSc, and Dorien Feyaerts, PhD
More webinars
WebinarUsing plasma proteomics to understand Alzheimer’s and other brain diseases
Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.
WebinarProteomics for precision neuroscience: the power of protein analysis
This webcast highlights how academic, industry and government researchers are directly measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.
WebinarCorrelation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes
In this webinar, Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on the use of the new SomaSignal(TM) NASH bundle test in a recently completed clinical trial.